NCT04509700 is a Phase 2 clinical trial of Parsaclisib in B-Cell Malignancies, sponsored by Incyte Corporation.

Who is sponsoring NCT04509700?

NCT04509700 is sponsored by Incyte Corporation.

What drugs are being tested in NCT04509700?

Interventions in NCT04509700: Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib, parsaclisib + ibrutinib.

What condition does NCT04509700 study?

NCT04509700 studies B-Cell Malignancies.

Is NCT04509700 still recruiting?

NCT04509700 is currently active, enrolled. Last updated 10 December 2025.

Last reviewed 2025-12-10 · How we verify

NCT04509700

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Active, enrolled Phase 2 Last updated 10 December 2025

What this trial tests

Phase 2 trial testing Parsaclisib in B-Cell Malignancies in 112 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

3 August 2020

Primary endpoint
30 September 2027

30 September 2027

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	112
Start date	3 August 2020
Primary completion	30 September 2027
Estimated completion	30 September 2027
Sites	105 locations across Denmark, France, Italy, Japan, Belgium, Austria, Sweden, United Kingdom

Drugs / interventions tested

Parsaclisib — full drug profile →
parsaclisib + itacitinib — full drug profile →
parsaclisib + ruxolitinib — full drug profile →
parsaclisib + ibrutinib — full drug profile →

Conditions studied

B-Cell Malignancies — all drugs for B-Cell Malignancies →

Sponsor

Incyte Corporation — full company profile →

Who can join

18 and older, any sex, with B-Cell Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.
Luo Y, Alexander M, Gadina M, O'Shea JJ, et al · · 2021 · cited 92× · PMID 34625141 · DOI 10.1016/j.jaci.2021.08.004
Small-molecule agents for cancer immunotherapy.
Wang F, Fu K, Wang Y, Pan C, et al · · 2024 · cited 41× · PMID 38486980 · DOI 10.1016/j.apsb.2023.12.010
Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?
Klein K, Stoiber D, Sexl V, Witalisz-Siepracka A. · · 2021 · cited 22× · PMID 34073410 · DOI 10.3390/cancers13112611
Molecular Basis of Oncogenic PI3K Proteins.
Sheng Z, Beck P, Gabby M, Habte-Mariam S, et al · · 2024 · cited 1× · PMID 39796708 · DOI 10.3390/cancers17010077

Verify or expand the search:

Other trials of Parsaclisib

Trials testing the same drug.

NCT07149818 — A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolyti · not yet recruiting
NCT05083208 — PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma · Phase 1 · terminated
NCT04774068 — Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas · Phase 1 · completed
NCT04323956 — Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma · Phase 1 · active not recruiting
NCT04142554 — Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer · Phase 1 · withdrawn

Other recruiting trials for B-Cell Malignancies

Currently open trials in the same condition.

NCT05683717 — A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies · Phase 1 · recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04509700 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 10 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04509700.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing